晚期胆囊癌应用吉西他滨联合替吉奥方案化疗的临床疗效  

Clinical efficacy of gemcitabine combined with tegafur in the chemotherapy of advanced gall bladder cancer

作　　者：杨金珠[1] 

机构地区：[1]合肥市第三人民医院肿瘤内科,合肥230022

出　　处：《肝胆外科杂志》2016年第3期196-197,共2页Journal of Hepatobiliary Surgery

摘　　要：目的探索晚期胆囊癌中吉西他滨联合替吉奥化疗的近期临床疗效和毒副反应。方法对20例晚期胆囊癌患者采用吉西他滨联合替吉奥方案化疗,吉西他滨1000 mg/m2,第1、5天静脉给药;替吉奥60 mg/m2/d,分两次口服,持续口服14天,三周为1周期,至少应用两周期,两疗程后评价患者的疗效、毒副反应等。结果入组20例均可评价疗效,治疗后完全缓解1例,部分缓解5例、稳定8例、进展6例,总有效率为30%,肿瘤控制率70%。无严重不良事件发生,无1例死亡,主要的不良反应为骨髓抑制、恶心呕吐、皮疹、肝功能损害。结论晚期胆囊癌应用吉西他滨联合替吉奥化疗的近期疗效较好,毒性反应较轻,患者耐受性可。Objective To explore the efficacy and toxicity of combination chemotherapy with gemcitabine and tegafur in the treatment of advanced gall bladder cancer. Methods Twenty patients with advanced gall bladder cancer received gemcitabine and tegafur combination regimen （gemcitabine： 1000 mg/m2 though intravenous on day 1 and 5 plus tegafur 60 mg/m2/d, twice daily during day 1 - 14）. The regimen was repeated at least two cycles of three weeks each and the clinical response was recorded at two weeks after treatment. Results Of the 20 patients, the overall response rate was 30% , and the clinical benefit response was 70% , including 1 pa- tient with complete remission and 5 patients with partial remission. The symptoms were stable in 8 patients and progressive in 6 patients. There was no severe complication or death observed. The most frequent treatment-related adverse event were hematological toxicity, nausea ,vomiting,rash and hepatic function impairment. Conclusion Gemcitabine combined with tegafur in the chemotherapy of patients with advanced gall bladder cancer has good short-term effect with minimal adverse reaction and can be tolerated well.

关 键 词：晚期胆囊癌 吉西他滨 替吉奥 化疗 

分 类 号：R657.4[医药卫生—外科学]